192 related articles for article (PubMed ID: 21705259)
1. Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study.
Tateno F; Sakakibara R; Yokoi Y; Kishi M; Ogawa E; Uchiyama T; Yamamoto T; Yamanishi T; Takahashi O
Parkinsonism Relat Disord; 2011 Nov; 17(9):662-6. PubMed ID: 21705259
[TBL] [Abstract][Full Text] [Related]
2. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Liu Z; Sakakibara R; Odaka T; Uchiyama T; Uchiyama T; Yamamoto T; Ito T; Asahina M; Yamaguchi K; Yamaguchi T; Hattori T
Mov Disord; 2005 Jun; 20(6):680-6. PubMed ID: 15719424
[TBL] [Abstract][Full Text] [Related]
3. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy.
Sakakibara R; Odaka T; Uchiyama T; Liu R; Asahina M; Yamaguchi K; Yamaguchi T; Yamanishi T; Hattori T
Mov Disord; 2004 Aug; 19(8):924-9. PubMed ID: 15300657
[TBL] [Abstract][Full Text] [Related]
4. Colonic transit time and rectoanal videomanometry in Parkinson's disease.
Sakakibara R; Odaka T; Uchiyama T; Asahina M; Yamaguchi K; Yamaguchi T; Yamanishi T; Hattori T
J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):268-72. PubMed ID: 12531969
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of bowel symptoms in Parkinson's disease.
Krogh K; Ostergaard K; Sabroe S; Laurberg S
Acta Neurol Scand; 2008 Jan; 117(1):60-4. PubMed ID: 18095955
[TBL] [Abstract][Full Text] [Related]
7. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
8. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
10. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Aarli JA; Gilhus NE
Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
[TBL] [Abstract][Full Text] [Related]
11. [Autonomic disorders in Parkinson's disease].
Gołab-Janowska M; Budzianowska A; Honczarenko K
Ann Acad Med Stetin; 2011; 57(1):11-5; discussion 16. PubMed ID: 22593985
[TBL] [Abstract][Full Text] [Related]
12. A study of salivary secretion in Parkinson's disease.
Bagheri H; Damase-Michel C; Lapeyre-Mestre M; Cismondo S; O'Connell D; Senard JM; Rascol O; Montastruc JL
Clin Neuropharmacol; 1999; 22(4):213-5. PubMed ID: 10442250
[TBL] [Abstract][Full Text] [Related]
13. Constipation in Parkinson's disease: objective assessment and response to psyllium.
Ashraf W; Pfeiffer RF; Park F; Lof J; Quigley EM
Mov Disord; 1997 Nov; 12(6):946-51. PubMed ID: 9399219
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease.
Sriranjini SJ; Ganesan M; Datta K; Pal PK; Sathyaprabha TN
Neurol India; 2011; 59(5):659-63. PubMed ID: 22019646
[TBL] [Abstract][Full Text] [Related]
15. Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation.
Ashraf W; Pfeiffer RF; Quigley EM
Mov Disord; 1994 Nov; 9(6):655-63. PubMed ID: 7845407
[TBL] [Abstract][Full Text] [Related]
16. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
17. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.
Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O
J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782
[TBL] [Abstract][Full Text] [Related]
18. Carbidopa/levodopa pharmacy errors in Parkinson's disease.
Khadem NR; Nirenberg MJ
Mov Disord; 2010 Dec; 25(16):2867-71. PubMed ID: 20818662
[TBL] [Abstract][Full Text] [Related]
19. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
